Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 10/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536464 | 0.93 | TBXAS1 (0.41) | TBXAS1CACNA1BMEN1LMNAKMT2A | |
| SCHEMBL3537912 | 0.84 | PPARG (0.37) | ALDH1A1KDM4E | |
| SCHEMBL3538685 | 0.84 | LCK (0.45) | CACNA1BALDH1A1KDM4ESCN9A | |
| SCHEMBL3535912 | 0.83 | LSS (0.38) | KMT2ASCN9A | |
| SCHEMBL3536043 | 0.78 | MMP1 (0.44) | ALDH1A1 | |
| SCHEMBL1021791 | 0.77 | TBXAS1 (0.46) | TBXAS1CACNA1BMEN1LMNAKMT2A | |
| SCHEMBL3534117 | 0.76 | MMP1 (0.40) | KMT2AALDH1A1 | |
| SCHEMBL1021792 | 0.76 | TBXAS1 (0.44) | TBXAS1CACNA1BMEN1LMNAKMT2A | |
| SCHEMBL3538924 | 0.74 | MMP1 (0.45) | TBXAS1CACNA1BLMNAALDH1A1 | |
| SCHEMBL1022410 | 0.74 | MMP1 (0.54) | TBXAS1CACNA1BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858619-B2 | Substituted tetrahydroisochinolines as MMP inhibitors, related production method and use as medicine | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-20080090821-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090821-A1 | SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE | MMP9, MMP3, MMP2 | TBXAS1 121/4885CACNA1B 1218/4885MEN1 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.